Northwest Biotherapeutics Releases Phase III Data for DCVax(R)-L and Secures New Financing
NEW YORK, NY / ACCESSWIRE / November 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Northwest Biotherapeutics (NWBO), a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies
DCVax®-L for Glioblastoma is the company's lead product for the treatment of newly diagnosed Glioblastoma. The company stock has moved from $.214 to $.29 in recent days as the company released data from its DCVax®-L phase III study.
Pipeline and a full comprehensive analyst review of NWBO READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/northwest-biotherapeutics/
On November 13th, the company announced aggregate financing of $5 million from long-term angel investors. The Company also agreed with the Company's CEO, Linda Powers, on further extensions of the Demand Notes relating to the $5.4 million of funding which Ms. Powers provided to the Company in February, March, and April of 2018 as a short-term bridge.
DCVax clinical trials, Pipeline review, financial summary and more here READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/northwest-biotherapeutics/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT:
SOURCE: Traders News Source
